ANI PHARMACEUTICALS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 65.49 USD | +2.03% |
|
+7.82% | +18.77% |
| 06-26 | HC Wainwright Adjusts ANI Pharmaceuticals Price Target to $94 From $87, Maintains Buy Rating | MT |
| 06-24 | Top Midday Gainers | MT |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 733 | 348.4 | 771.5 | 655.9 | 1,052 | 1,271 | - | - |
| Enterprise Value (EV) 1 | 733 | 348.4 | 771.5 | 655.9 | 1,052 | 1,295 | 1,298 | 1,271 |
| P/E ratio | 123 x | -15.4 x | -13.6 x | -13.2 x | 64.9 x | 39 x | 25 x | 14.8 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 3.55 x | 1.67 x | 3.57 x | 2.07 x | 2.16 x | 2.29 x | 2.03 x | 1.96 x |
| EV / Revenue | 3.55 x | 1.67 x | 3.57 x | 2.07 x | 2.16 x | 2.34 x | 2.07 x | 1.96 x |
| EV / EBITDA | 8.81 x | 5.19 x | 11.9 x | 11.7 x | 7.86 x | 9.07 x | 7.29 x | 6.76 x |
| EV / FCF | - | - | 1,008 x | -16.4 x | 9.56 x | 19.1 x | 12.4 x | 10.8 x |
| FCF Yield | - | - | 0.1% | -6.11% | 10.5% | 5.23% | 8.06% | 9.28% |
| Price to Book | - | - | - | - | - | 2.71 x | 2.47 x | - |
| Nbr of stocks (in thousands) | 11,886 | 11,996 | 16,742 | 16,304 | 19,083 | 19,409 | - | - |
| Reference price 2 | 61.67 | 29.04 | 46.08 | 40.23 | 55.14 | 65.49 | 65.49 | 65.49 |
| Announcement Date | 20-02-27 | 21-03-09 | 22-03-15 | 23-03-09 | 24-02-29 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 206.5 | 208.5 | 216.1 | 316.4 | 486.8 | 554.1 | 627.3 | 647 |
| EBITDA 1 | 83.16 | 67.12 | 64.84 | 55.86 | 133.8 | 142.8 | 177.9 | 188 |
| EBIT 1 | 16.35 | -16.02 | -39.79 | -35.28 | 46.97 | 56.53 | 78.89 | 97.6 |
| Operating Margin | 7.92% | -7.68% | -18.41% | -11.15% | 9.65% | 10.2% | 12.58% | 15.09% |
| Earnings before Tax (EBT) 1 | 3.157 | -25.96 | -56.06 | -62.66 | 19.87 | 45.44 | 60.54 | 103.3 |
| Net income 1 | 6.094 | -22.55 | -42.79 | -49.52 | 17.15 | 34.09 | 47.7 | 80.6 |
| Net margin | 2.95% | -10.82% | -19.8% | -15.65% | 3.52% | 6.15% | 7.61% | 12.46% |
| EPS 2 | 0.5000 | -1.880 | -3.400 | -3.050 | 0.8500 | 1.680 | 2.620 | 4.425 |
| Free Cash Flow 1 | - | - | 0.765 | -40.08 | 110.1 | 67.68 | 104.6 | 117.9 |
| FCF margin | - | - | 0.35% | -12.67% | 22.61% | 12.22% | 16.68% | 18.22% |
| FCF Conversion (EBITDA) | - | - | 1.18% | - | 82.27% | 47.41% | 58.79% | 62.7% |
| FCF Conversion (Net income) | - | - | - | - | 641.78% | 198.52% | 219.31% | 146.28% |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 20-02-27 | 21-03-09 | 22-03-15 | 23-03-09 | 24-02-29 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 60.93 | 64.48 | 73.86 | 83.82 | 94.23 | 106.8 | 116.5 | 131.8 | 131.7 | 137.4 | 128.6 | 136.5 | 151.6 | 159.9 | 168 |
| EBITDA 1 | 16.2 | 4.273 | 9.861 | 19.55 | 23.33 | 33.01 | 34.12 | 36.48 | 30.2 | 37.63 | 28.33 | 34.38 | 43.33 | 40.65 | 44.06 |
| EBIT 1 | -23.72 | -19.2 | -12.91 | -4.995 | 1.82 | 9.895 | 12.4 | 17.95 | 6.726 | 20.31 | 6.292 | 11.43 | 18.5 | 16.57 | 19.66 |
| Operating Margin | -38.94% | -29.77% | -17.48% | -5.96% | 1.93% | 9.27% | 10.64% | 13.61% | 5.11% | 14.78% | 4.89% | 8.37% | 12.2% | 10.36% | 11.7% |
| Earnings before Tax (EBT) 1 | -30.85 | -25.9 | -18.82 | -12.22 | -5.728 | 2.165 | 5.249 | 11.51 | 0.947 | 25.34 | 1.742 | 6.982 | 11.4 | 7.072 | 10.66 |
| Net income 1 | -24.33 | -20.54 | -15.33 | -9.006 | -4.65 | 1.033 | 5.838 | 9.534 | 0.749 | 18.21 | 1.394 | 5.586 | 9.11 | 5.658 | 8.528 |
| Net margin | -39.93% | -31.85% | -20.76% | -10.74% | -4.93% | 0.97% | 5.01% | 7.23% | 0.57% | 13.25% | 1.08% | 4.09% | 6.01% | 3.54% | 5.08% |
| EPS 2 | -1.720 | -1.270 | -0.9400 | -0.5500 | -0.2800 | 0.0600 | 0.2900 | 0.4500 | 0.0400 | 0.8200 | 0.0667 | 0.3033 | 0.4767 | 0.2700 | 0.4100 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 22-03-15 | 22-05-10 | 22-08-08 | 22-11-09 | 23-03-09 | 23-05-08 | 23-08-09 | 23-11-08 | 24-02-29 | 24-05-10 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | 24.2 | 26.5 | - |
| Net Cash position 1 | - | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | 0.1692 x | 0.1489 x | - |
| Free Cash Flow 1 | - | - | 0.77 | -40.1 | 110 | 67.7 | 105 | 118 |
| ROE (net income / shareholders' equity) | - | - | - | - | - | 18.2% | 19.5% | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | 7.2% | 9% | - |
| Assets 1 | - | - | - | - | - | 473.5 | 530.1 | - |
| Book Value Per Share 2 | - | - | - | - | - | 24.20 | 26.50 | - |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex 1 | 6.64 | 6.14 | 2.56 | 8.88 | 8.87 | 13.6 | 13.8 | 16.7 |
| Capex / Sales | 3.21% | 2.94% | 1.18% | 2.81% | 1.82% | 2.46% | 2.19% | 2.57% |
| Announcement Date | 20-02-27 | 21-03-09 | 22-03-15 | 23-03-09 | 24-02-29 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
65.49
USD
Average target price
83
USD
Spread / Average Target
+26.74%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +18.77% | 1.25B | |
| +54.61% | 815B | |
| +44.25% | 654B | |
| -6.33% | 354B | |
| +20.62% | 337B | |
| +10.44% | 302B | |
| +18.45% | 247B | |
| +2.09% | 229B | |
| +13.03% | 219B | |
| +8.61% | 171B |
- Stock Market
- Equities
- ANIP Stock
- Financials ANI Pharmaceuticals, Inc.
